Tier 2 — strong

Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection

Ruiz-Herrera VV, Navarro-Lara SA, Andrade-Villanueva JF, Alvarez-Zavala M, Sánchez-Reyes K, Toscano-Piña M, Méndez-Clemente AS, Martínez-Ayala P, Valle-Rodríguez A, González-Hernández LA
International journal of STD & AIDS 2023 34(14):1042-1052

Bibliography

PubMed
PMID 37611246
DOI
10.1177/09564624231196600
Funding
Indexed support: Programa de Impulso a la Investigacionn. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignDouble-blind placebo-controlled pilot randomized trial
ModelHuman participants; see population
Sample43 randomized; 36 completed and analyzed
InterventionBerberine 500 mg three times/day versus placebo in treated HIV
Duration20 weeks
EndpointsFasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability

What the study showed, in plain terms

This small trial in virologically suppressed adults reported selected weight and metabolic improvements.

Key findings

  • This small trial in virologically suppressed adults reported selected weight and metabolic improvements.

What this study can and cannot tell us

Small completer analysis, concomitant antiretroviral therapy and limited interaction data restrict generalization.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial
Mansour A et al. · European journal of nutrition · 2025
Tier 2
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
Nikseresht M et al. · Physiological reports · 2024
Tier 2
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
Panigrahi A et al. · BMC endocrine disorders · 2023
Tier 2
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
Rondanelli M et al. · European review for medical and pharmacological sciences · 2023
Tier 4
Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
Wang S et al. · Gut microbes · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology